EyePoint Pharma 
Welcome,         Profile    Billing    Logout  
 6 Products   5 Diseases   6 Products   15 Trials   651 News 


«123456
  • ||||||||||  Iluvien (fluocinolone acetonide) / Alimera Sciences, EyePoint Pharma
    Journal:  ILUVIEN technology in the treatment of center-involving diabetic macular edema: a review of the literature. (Pubmed Central) -  Apr 30, 2019   
    Recent adoption of novel alternative drug delivery options has led to the development of sustained release ocular implants with longer duration of action with less injection frequency. This article will review the pharmacology and clinical data in terms of efficacy, safety and benefits of the sustained release steroid implants in treatment of DME with special emphasis on the fluocinolone acetonide ILUVIEN implant.
  • ||||||||||  Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
    Enrollment closed, Enrollment change, Trial primary completion date:  IRISS: Iluvien Registry Safety Study (clinicaltrials.gov) -  Oct 25, 2017   
    P=N/A,  N=559, Active, not recruiting, 
    The FAc 0.2 μg/day implant provided good value for money compared with other established treatments, especially in pseudophakic patients. Recruiting --> Active, not recruiting | N=800 --> 559 | Trial primary completion date: Dec 2018 --> Jan 2020
  • ||||||||||  Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
    Trial primary completion date:  Fluocinolone Acetonide Insert (ILUVIEN®) for Diabetic Macular Edema (FAD) Study (clinicaltrials.gov) -  Aug 22, 2017   
    P4,  N=0, Withdrawn, 
    Recruiting --> Active, not recruiting | N=800 --> 559 | Trial primary completion date: Dec 2018 --> Jan 2020 Trial primary completion date: Mar 2019 --> Aug 2017
  • ||||||||||  Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
    Enrollment change, Trial initiation date, Trial withdrawal, Trial primary completion date:  Fluocinolone Acetonide Insert (ILUVIEN®) for Diabetic Macular Edema (FAD) Study (clinicaltrials.gov) -  Apr 4, 2017   
    P4,  N=0, Withdrawn, 
    Initiation date: Aug 2006 --> Feb 2016 | Trial primary completion date: Apr 2017 --> Mar 2018 N=50 --> 0 | Initiation date: Sep 2016 --> Mar 2017 | Recruiting --> Withdrawn | Trial primary completion date: Sep 2018 --> Mar 2019
  • ||||||||||  Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
    Trial completion:  RESPOND: A Pilot Study on the Effect and Safety of Iluvien (clinicaltrials.gov) -  Mar 10, 2017   
    P4,  N=12, Completed, 
    N=50 --> 0 | Initiation date: Sep 2016 --> Mar 2017 | Recruiting --> Withdrawn | Trial primary completion date: Sep 2018 --> Mar 2019 Active, not recruiting --> Completed
  • ||||||||||  Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
    Enrollment closed, P4 data, Enrollment change, Trial primary completion date:  PALADIN: Phase 4 IOP Signals Associated With ILUVIEN® (clinicaltrials.gov) -  Jan 6, 2017   
    P4,  N=153, Active, not recruiting, 
    Active, not recruiting --> Completed Enrolling by invitation --> Active, not recruiting | N=300 --> 153 | Trial primary completion date: Apr 2019 --> Dec 2019
  • ||||||||||  Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
    Enrollment status, P4 data:  PALADIN: Phase 4 IOP Signals Associated With ILUVIEN® (clinicaltrials.gov) -  Mar 31, 2016   
    P4,  N=300, Enrolling by invitation, 
    Enrolling by invitation --> Active, not recruiting | N=300 --> 153 | Trial primary completion date: Apr 2019 --> Dec 2019 Recruiting --> Enrolling by invitation
  • ||||||||||  Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
    Enrollment open, Trial primary completion date, Surgery:  Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery (clinicaltrials.gov) -  Jan 15, 2016   
    P3,  N=180, Recruiting, 
    Recruiting --> Enrolling by invitation Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2015 --> Dec 2016
  • ||||||||||  Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
    Enrollment change, Trial termination:  Observational Study to Assess the Effect of Iluvien (clinicaltrials.gov) -  Aug 11, 2015   
    P=N/A,  N=25, Terminated, 
    Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2015 --> Dec 2016 N=500 --> 25 | Active, not recruiting --> Terminated
  • ||||||||||  Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
    Enrollment closed:  Observational Study to Assess the Effect of Iluvien (clinicaltrials.gov) -  Jun 6, 2015   
    P=N/A,  N=500, Active, not recruiting, 
    N=500 --> 25 | Active, not recruiting --> Terminated Recruiting --> Active, not recruiting
  • ||||||||||  Medidur (fluocinolone acetonide micro-insert intravitreal implant) / EyePoint Pharma, Alimera Sci
    Enrollment change:  Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy (clinicaltrials.gov) -  May 29, 2015   
    P2,  N=17, Terminated, 
    Recruiting --> Active, not recruiting N=40 --> 17
  • ||||||||||  Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
    Enrollment open, P4 data, Phase classification:  PALADIN: Phase 4 IOP Signals Associated With ILUVIEN® (clinicaltrials.gov) -  May 22, 2015   
    P4,  N=300, Recruiting, 
    N=40 --> 17 Phase classification: P=N/A --> P4 | Not yet recruiting --> Recruiting
  • ||||||||||  Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
    New P4 trial, P4 data:  PALADIN: Phase 4 IOP Signals Associated With ILUVIEN® (clinicaltrials.gov) -  Apr 28, 2015   
    P4,  N=300, Recruiting, 
    Phase classification: P=N/A --> P4 | Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
  • ||||||||||  Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
    Enrollment closed, Enrollment open:  RESPOND: A Pilot Study on the Effect and Safety of Iluvien (clinicaltrials.gov) -  Mar 19, 2015   
    P4,  N=12, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting
  • ||||||||||  Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
    New P4 trial:  RESPOND: A Pilot Study on the Effect and Safety of Iluvien (clinicaltrials.gov) -  Feb 10, 2015   
    P4,  N=12, Recruiting, 
  • ||||||||||  Iluvien (fluocinolone acetonide) / Alimera Sci, EyePoint Pharma
    Enrollment open:  IRISS: Iluvien Registry Safety Study (clinicaltrials.gov) -  Apr 7, 2014   
    P=N/A,  N=800, Recruiting, 
    Trial primary completion date: Dec 2014 --> Apr 2017 Not yet recruiting --> Recruiting
  • ||||||||||  Medidur (fluocinolone acetonide micro-insert intravitreal implant) / EyePoint Pharma, Alimera Sci
    Enrollment closed:  Fluocinolone Acetonide Intravitreal Inserts in Geographic Atrophy (clinicaltrials.gov) -  Nov 19, 2013   
    P2,  N=40, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
  • ||||||||||  Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
    Trial termination, Surgery:  Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients (clinicaltrials.gov) -  Sep 15, 2013   
    P2,  N=42, Terminated, 
    Recruiting --> Active, not recruiting Active, not recruiting --> Terminated; Study C11-01 started
  • ||||||||||  Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
    Enrollment change, Surgery:  Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients (clinicaltrials.gov) -  Sep 15, 2013   
    P2,  N=42, Terminated, 
    Active, not recruiting --> Terminated; Study C11-01 started N=228 --> 42
  • ||||||||||  Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
    Enrollment change, Surgery:  Efficacy and Safety of IBI-10090 in Ocular Surgery Patients (clinicaltrials.gov) -  Jul 14, 2013   
    P2,  N=172, Completed, 
    N=228 --> 42 N=228 --> 172
  • ||||||||||  Dexycu (dexamethasone intraocular injection) / EyePoint Pharma, Ocumension Therap
    Trial completion, Surgery:  Efficacy and Safety of IBI-10090 in Ocular Surgery Patients (clinicaltrials.gov) -  Jul 14, 2013   
    P2,  N=172, Completed, 
    N=228 --> 172 Recruiting --> Completed
  • ||||||||||  Retisert (fluocinolone acetonide intravitreal implant) / Bausch Health, EyePoint Pharma
    Trial completion:  Fluocinolone Acetonide Implant for Retinal Vein Occlusion (RVO) (clinicaltrials.gov) -  Oct 22, 2012   
    P0,  N=30, Completed, 
    Recruiting --> Completed Recruiting --> Completed
  • ||||||||||  Retisert (fluocinolone acetonide intravitreal implant) / Bausch Health, EyePoint Pharma
    Trial completion:  Prophylactic Anecortave Acetate in Patients With a Retisert Implant (clinicaltrials.gov) -  Jun 2, 2012   
    P1,  N=12, Completed, 
    N=24 --> 12 Active, not recruiting --> Completed